Samlyn Capital’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Samlyn Capital’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-616,040	Closed	-$2.05M	–	169
2016 Q3	$2.05M	Sell	616,040 -2	-0%	-$8	0.05%	111
2016 Q2	$2.65M	Hold	616,042	–	–	0.06%	104
2016 Q1	$3.47M	Hold	616,042	–	–	0.07%	83
2015 Q4	$10.6M	Hold	616,042	–	–	0.22%	75
2015 Q3	$13M	Buy	616,042 +11,390	+2%	+$390K	0.24%	78
2015 Q2	$29.9M	Buy	604,652 +290,799	+93%	+$17.4M	0.48%	74
2015 Q1	$24.6M	Sell	313,853 -255,219	-45%	-$15.8M	0.39%	77
2014 Q4	$34.5M	Buy	569,072 +339,172	+148%	+$17M	0.6%	65
2014 Q3	$9.79M	Buy	+229,900	New	+$12.3M	0.2%	86

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $944M AUM 90.26% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Samlyn Capital's OREX Position: Q4 2016 in Review

Samlyn Capital sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2016, closing a stake of 616,040 shares — an estimated $2.05M sold.

Samlyn Capital first reported a position in OREX in Q3 2014 and held it in 9 quarters. The position peaked at $34.5M in Q4 2014. 53 funds tracked by Wall St. Rank hold OREX as of Q4 2016.

Samlyn Capital reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
Samlyn Capital sold 616,040 Orexigen Therapeutics, Inc. shares in Q4 2016, an estimated $2.05M.
Samlyn Capital first reported a position in Orexigen Therapeutics, Inc. in Q3 2014 and held it in 9 quarters.
Samlyn Capital's Orexigen Therapeutics, Inc. position peaked at $34.5M in Q4 2014.
53 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2016.

Based on Samlyn Capital's 13F filing for Q4 2016, filed 14 Feb 2017.